Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02663271 : TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
PhasePhase 2
AgesMin: 22 Years Max: N/A
Inclusion Criteria:

- Histologically confirmed GBM, WHO grade IV. GBM variants and secondary GBM are allowed
in any recurrence (including multiple) and have been treated with radiation and

- Unequivocal evidence of tumor progression during prior bevacizumab treatment per RANO

- Patient is a candidate for, and agrees to proceed with additional bevacizumab

- Male or female at least 22 years of age or older.

- Karnofsky Performance Scale (KPS) ? 60%.

- Planned treatment with TTFields therapy.

- Women of childbearing potential must have a negative serum or urine pregnancy test
within 14 days of treatment.

- Participants of childbearing/reproductive potential must use effective contraception.

- Participants must be able to understand and willing to comply with protocol
requirements as assessed by the investigator.

- Signed informed consent according to institutional guidelines prior to registration.

Exclusion Criteria:

- Inability to undergo brain MRI due to medical or personal reasons.

- Currently receiving investigational agents that are intended as treatments of
recurrent GBM.

- Skull defect such as missing bone or bullet fragments.

- Uncontrolled intercurrent illness including, but not limited to symptomatic congestive
heart failure, unstable angina pectoris, heart attack within the previous 12 months,
stroke (except for TIA) within the previous 6 months, or psychiatric illness/social
situations that would limit compliance with study requirements.

- Intracranial hemorrhage except for tumor associated micro hemorrhage.

- Women who are pregnant or breastfeeding.

- Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, vagus
nerve stimulator, and other implanted electronic devices in the brain or the spinal

- Tumor located entirely in the infratentorium.

- History of hypersensitivity to hydrogel.
LinksPermanent Link to THIS page:      |      Link to official listing
Gainesville, Florida
Facility: University of Florida
Investigator: David D Tran, MD, PhD
Contact: Sarah Andrews, RN Phone: 352-273-7891
Click HERE to send email to this center

Saint Louis, Missouri
Facility: Washington University
Investigator: George Ansstas, M.D.
Contact: Grayson Talcott, BS Phone: 314-273-0656
Click HERE to send email to this center

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites